Americafirst Capital Management LLC acquired a new stake in shares of CVS Health Corp (NYSE:CVS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,156 shares of the pharmacy operator’s stock, valued at approximately $419,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC raised its holdings in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC grew its position in CVS Health by 330.3% during the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares during the period. Arcadia Investment Management Corp MI grew its position in CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after buying an additional 726 shares during the period. MPS Loria Financial Planners LLC bought a new stake in CVS Health during the second quarter valued at approximately $119,000. Finally, Captrust Financial Advisors bought a new stake in CVS Health during the second quarter valued at approximately $155,000. 80.81% of the stock is owned by hedge funds and other institutional investors.
CVS Health Corp (CVS) opened at $70.11 on Wednesday. The firm has a market cap of $71,020.00, a P/E ratio of 11.88, a price-to-earnings-growth ratio of 1.16 and a beta of 0.92. CVS Health Corp has a 12-month low of $66.45 and a 12-month high of $84.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52.
CVS Health (NYSE:CVS) last posted its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The business had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. During the same period in the prior year, the business posted $1.71 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. sell-side analysts anticipate that CVS Health Corp will post 6.47 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.85%. CVS Health’s dividend payout ratio is 33.90%.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.61% of the stock is currently owned by corporate insiders.
Several brokerages recently issued reports on CVS. Citigroup set a $77.00 target price on shares of CVS Health and gave the company a “neutral” rating in a research report on Tuesday. Needham & Company LLC set a $98.00 target price on shares of CVS Health and gave the company a “buy” rating in a research report on Friday, February 9th. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann set a $85.00 target price on shares of CVS Health and gave the company a “buy” rating in a research report on Friday, February 9th. Finally, Robert W. Baird restated a “hold” rating and set a $77.00 target price on shares of CVS Health in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. CVS Health currently has a consensus rating of “Buy” and a consensus price target of $87.82.
ILLEGAL ACTIVITY WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/14/americafirst-capital-management-llc-takes-419000-position-in-cvs-health-corp-cvs.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.